Medical Research


At CAF, Medical Reseach is Key


Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requries additional funding: The Cooley’s Anemia Foundation may be just what you need. CAF is now accepting applications for its 2016-2017 Fellowship and Research Grant programs and we encourage you to apply.

CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.

Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and GeneTherapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.

CAF Funds $375,000 in Important Thalassemia Research Areas

Monday, July 15th, 2013

July 15, 2013 – What would motivate a person with thalassemia to make changes to improve adherence to therapy?  Can metabolic substances in a person with thalassemia give a clue to how iron is loading in his/her heart?  Would moving the fetal hemoglobin gene cause it to create more fetal hemoglobin? These are just some […]

American Heart Association Releases Statement on Cardiac Dysfunction in Thalassemia Major

Thursday, June 20th, 2013

June 20, 2013 – The American Heart Association (AHA)  has released a consensus statement on “Cardiovascular Function and Treatment in Beta-Thalassemia Major.” Published online in the AHA journal Circulation, the document states in part that “central to early identification of cardiac iron overload in TM (thalassemia major) is the estimation of cardiac iron by cardiac […]

June 15 is Deadline for International Thalassemia Award Applications

Wednesday, May 1st, 2013

May 1, 2013 – The deadline for applying for one of the 2013 Sultan Bin Khalifa International Thalassemia Awards,established by H.H. Dr. Sheikh Sultan Bin Khalifa Al Nahyan in partnership with the Thalassaemia International Federation, is June 15. The Awards are intended to recognize outstanding contributions in thalassemia by medical professionals, researchers, patients, parents and organizations.  […]

Acceleron Developing Thalassemia Treatments

Monday, January 28th, 2013

January 28, 2013 – Acceleron, a biopharmaceutical company based in Cambridge, Massahusetts, in collaboration with Summit, New Jersey-based pharmaceutical partner Celgene Corporation, is developing two programs, sotatercept (formerly called ACE-011) and ACE-536, for the treatment of beta-thalassemia. Sotatercept and ACE-536 are biologic drugs that increase hemoglobin and red blood cells levels by promoting the maturation […]

Exjade Approved for Use in Non-Transfusion-Dependent Thalassemia

Wednesday, January 23rd, 2013

January 23, 2013 – From an FDA press release: The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). NTDT is a milder form of thalassemia that does […]

U.S.-Based Gene Therapy Study Begins Treating Participants

Thursday, January 10th, 2013

January 10, 2013 – CAF has learned that the first U.S.-based clinical trial in gene therapy for beta-thalassemia has begun treating trial participants.   The Phase 1 study, the official title of which is “ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene,” is […]